Germany · Biotechnology startup
Germany · Tubulis
Tubulis is a chemotherapeutic medication developer specializing in cancer and chronic disease treatment.
Funding reportedLast round: Series B
What company datasets say Tubulis raised
Funding, as reported
Reported in all400.6Min the source's currency
Rounds4
Last roundSeries B
Last round dateMar 2024
Investors listed13
Founders and team
From Tubulis's own website: 56 on the team.
- Andreas MontagVice President Finance
- Dr. Annette VoglVice President Biology and Translational Research
- Dr. Armin WeidmannSenior Vice President Quality
- Dr. Marc-André KasperVice President Chemistry and Early Development
- Dr. Moetaz B. AlbizemSenior Vice President and Head of Clincal Operations
- Dr. Olivier MarcqSenior Vice President CMC
- Dr. Yariv HouvrasVice President Clinical and Translational Development
- Mary Ann LumiquedVice President Program Management
- Ramola BhandarkarSenior Vice President Regulatory Affairs
- Bettina DeisenriederExecutive Assistant to the CEO
- Dr. Dominik SchumacherCEO
- Adriane KraheGlobal Head of HR
- Dr. Bernhard SeehausGlobal Head of Intellectual Property
- Eckart FreheHead of IT
- Anastasia KazanisSenior Operations Manager
- Andrea MathieuFinancial Operations Specialist
- Arijana PopadicOffice Manager
- Christina BauerHR Manager
And 38 more on the team.
On 4 portfolio pages
Investors who name them
Each firm lists Tubulis on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
Biotechnology in Germany
Startups like it
Is this your company?
Add your raise, your deck and your story, and put Tubulis in front of investors. Or tell us what we have wrong.